nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-D0535327·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Neurology and psychiatry·Subfield: Pharmacology·Basis: Full text·Type: Cross-sectional study

Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson's disease.

Ajalin et al.Ajalin, Al-Abdulrasul, Tuisku et al.·2026·Journal of Parkinson's disease·10.1177/1877718x261457830 ↗

Primary claim

Decreased CB1R availability in PD patients is correlated with episodic memory impairment and executive dysfunction, suggesting that the ECS has a role in the pathophysiology of cognitive symptoms in PD.

Tentative · cross-sectional associations in a cognitively preserved sample cannot establish impairment or a pathophysiological role
In brief

A useful second-tracer replication links CB1 receptor availability to selected cognitive scores in Parkinson’s disease, but limited confounding control constrains interpretation.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BackgroundThe endocannabinoid system (ECS) is important for several neurophysiological functions, including the regulation of emotions and cognitive processes. The most abundant brain cannabinoid receptor is cannabinoid receptor type 1 (CB1R). Several preclinical studies in Parkinson's disease (PD) models suggest that modulating CB1R may impact cognitive processing. However, there are very limited studies of the relation between CB1R and cognitive processing in PD patients.ObjectiveTo explore the relationship between CB1R availability and cognitive dysfunction in PD with [18F]FMPEP-d2 positron emission tomography (PET).MethodsA total of 23 individuals with PD underwent [18F]FMPEP-d2 PET to measure cerebral CB1R availability. Cognitive symptoms were evaluated using a standardized neuropsychological test battery covering various cognitive domains, such as episodic and working memory, executive functioning, language function, visuospatial function and attention, and were correlated with CB1R availability using voxel-wise regression analysis corrected for multiple comparisons using false discovery rate (FDR) at p < 0.01.ResultsPD patients with poorer performance in episodic memory tests showed lower CB1R availability, particularly in the cingulate, temporal, and visual cortices, and thalami. Also, PD patients with poorer executive functioning showed lower CB1R availability predominantly in the insulae, caudate nuclei, thalami, brainstem, and temporal cortices. No relationship was found between CB1R availability and language function, visuospatial function, or working memory capacity.ConclusionsDecreased CB1R availability in PD patients is correlated with episodic memory impairment and executive dysfunction, suggesting that the ECS has a role in the pathophysiology of cognitive symptoms in PD.Plain language summary titleProblems with Episodic Memory or Executive Functions are Related to Disturbances in Endocannabinoid System Functioning in Parkinson's Disease.

Key Claims

Primary finding · Tentative

Decreased CB1R availability in PD patients is correlated with episodic memory impairment and executive dysfunction, suggesting that the ECS has a role in the pathophysiology of cognitive symptoms in PD.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

cross-sectional associations in a cognitively preserved sample cannot establish impairment or a pathophysiological role

Abstract, Conclusions
Quote verified
Secondary · Supported

PD patients with poorer performance in episodic memory tests showed lower CB1R availability, particularly in the cingulate, temporal, and visual cortices, and thalami.

three episodic-memory measures showed corrected associations, though the small cross-sectional sample limits precision

Abstract, Results; Results, Figure 1
Quote verified
Secondary · Tentative

PD patients with poorer executive functioning showed lower CB1R availability predominantly in the insulae, caudate nuclei, thalami, brainstem, and temporal cortices.

the broad executive claim rests on TMT B-A while three other executive measures were null

Abstract, Results; Results, Figure 2
Quote verified
Secondary · Supported

No relationship was found between CB1R availability and language function, visuospatial function, or working memory capacity.

the specified tests were null, but the sample was underpowered to establish absence of association

Abstract, Results; Results, null-results paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Independent tracer extends sparse evidence

The study tests the CB1R–cognition relationship with [18F]FMPEP-d2 and absolute VT, complementing the earlier [18F]MK9470 study that used proportional scaling.

↳ Introduction; Discussion, comparison with the prior PET study

#methodological rigour

Multiple sensitivity analyses reported transparently

The paper reports voxelwise and across-test multiplicity control, partial-volume correction, exclusion of escitalopram users, and winsorized versus unwinsorized TMT B-A analyses.

↳ Methods, Statistical Analyses; Results, Figures 1–2; Discussion, medication and atrophy paragraphs

#positioning

Limitations inform the final interpretation

Amyloid co-pathology, medication, atrophy, small sample size, preserved cognition, and the need for longitudinal follow-up are connected to the scope of the conclusions.

↳ Discussion, limitations and Conclusion

Limitations

#methodological rigour

Confounding control remains too limited

The principal PET regressions include LEDD but not age, education, disease severity, depressive symptoms, or AD biomarker status, despite plausible relationships with cognition or CB1R availability.

↳ Methods, Statistical Analyses; Results, CSF Biomarkers

#reporting

Headline framing exceeds observed cognition

The title and Abstract refer to deficits, impairment, and executive dysfunction, although Table 2 reports no PD–control cognitive differences and only TMT B-A was significant among four executive measures.

↳ Title; Abstract; Results, Table 2 and null-results paragraph

#methodological rigour

Regional specificity is difficult to establish

The analysis used absolute VT without global normalization and produced clusters spanning extensive cortical and subcortical areas. The cluster-display threshold is not specified beyond showing significant clusters.

↳ Methods, Statistical Analyses; Results, Figures 1–2

Does this match your read? Add your assessment ↓

Nabu Commentary

The study provides a useful second-tracer examination of CB1R availability and cognition in PD, and its corrected voxelwise analyses are accompanied by several sensitivity checks. Its quality is constrained by a sample of 23 and principal regressions that adjust only for LEDD, leaving disease-related, demographic, and co-pathology confounding incompletely controlled. The title and Abstract also generalize from selected within-group associations to cognitive deficits and executive dysfunction even though Table 2 shows no cognitive difference from controls. The Discussion is more disciplined, directly comparing the closest PET study and acknowledging that prediction and temporal ordering require longitudinal evidence.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.2±0.2

Contribution
3.1

The study adds a second human PD dataset relating CB1R availability to cognition and uses a different ligand and absolute VT rather than proportional scaling. The advance remains incremental because it largely provides convergent exploratory evidence in 23 participants.

Introduction, final paragraphs; Discussion, comparison with the [18F]MK9470 study

Our findings also support the previous observations of the study using [18F]MK9470

Methodological Rigour
3.0

Voxelwise FDR correction, across-test adjustment, partial-volume analysis, medication sensitivity analysis, and transparent outlier handling support the analysis. Small sample size, adjustment only for LEDD, extensive clusters without global normalization, and restricted volunteer recruitment leave meaningful uncertainty.

Methods, Statistical Analyses; Results, Figures 1–2; Discussion, limitations

LEDD was set as a covariate.

Reporting
3.4

The methods-to-results chain and null findings are traceable, and the Discussion disclaims prediction from the cross-sectional design. The title and Abstract nonetheless describe deficits and broad executive dysfunction despite no cognitive group differences and only one significant executive measure.

Title; Abstract, Results and Conclusions; Results, Table 2; Discussion, Conclusion

We cannot conclude that reduced CB1R availability can predict cognitive decline in PD

Positioning
3.8

The Discussion directly compares tracer and scaling differences with the closest prior PET study and addresses amyloid co-pathology, medication, atrophy, sample size, and temporality. The contextual treatment is substantive, although age and education confounding are not carried into the interpretation.

Discussion, prior-study comparison and limitations paragraphs

given the cross-sectional design, this interpretation remains speculative

Reliability

Caveats4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyNoted

The acquisition-to-modelling description leaves the handling of a scan gap unexplained, and the numerical cluster-extent display threshold is not reported; neither omission establishes that the reported associations change.

Ethics approval: declared · Data availability: declared

Reference IntegrityClean

80 references in manuscript 80 of 80 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Parkinson's disease
Type of advanceEmpirical
Route to useSuggested
AdvanceConsolidates
BeneficiariesMedium
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on a single cross-sectional correlational PET study in 23 patients, with no experimental or longitudinal demonstration yet.

From the paper
“determine whether ECS-targeting medication could benefit in managing the non-motor symptoms of PD”

The conclusion names a possible real-world use, ECS-targeting medication for non-motor symptoms, but does not name who would act on these findings or how.

Pathway

Neurology researchers and drug developers could use these correlational findings to justify and design ECS-targeting trials for cognitive symptoms in Parkinson's disease.

Barrier

The evidence is a small cross-sectional correlation in 23 medicated patients, so causality and predictive value are unproven without larger longitudinal studies.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

    2026 · Clinical medicine

    Primary claim

    In adults with obesity and type 2 diabetes, once-weekly retatrutide over 80 weeks produced weight reduction of up to 18·8% from baseline with an estimated treatment difference of -13·8% versus placebo

    Well-supported
    Evidence Score
    4.2±0.1
    Reliability
    No concerns
  2. Pain as an assault on the self: An interpretative phenomenological analysis of the psychological impact of chronic benign low back pain

    Jonathan Ashley Smith, Mike Osborn · 2006 · Psychology and cognitive sciences

    Primary claim

    The notion of the self emerged in this study as an important aspect of the participants’ experience of chronic pain sensation, distress and disability.

    Supported
    Evidence Score
    3.5±0.1
    Reliability
    No concerns
  3. Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process

    Pozuelo Moyano, von Gunten, Mueller, et al. · 2026 · Clinical medicine

    Primary claim

    Experts agreed that the categorical definition of TRLLD should correspond to major depressive disorder in individuals aged ≥65 years who show insufficient response to two adequate antidepressant treatments, in the absence of dementia and medical conditions that could account for depressive symptoms.

    Supported
    Evidence Score
    3.7±0.2
    Reliability
    Caveats

How the rubric works →